314 related articles for article (PubMed ID: 35113367)
21. Pharmacogenetics Guidelines: Overview and Comparison of the DPWG, CPIC, CPNDS, and RNPGx Guidelines.
Abdullah-Koolmees H; van Keulen AM; Nijenhuis M; Deneer VHM
Front Pharmacol; 2020; 11():595219. PubMed ID: 33568995
[TBL] [Abstract][Full Text] [Related]
22. Pharmacogenetics testing (DPYD and UGT1A1) for fluoropyrimidine and irinotecan in routine clinical care: Perspectives of medical oncologists and oncology pharmacists.
Glewis S; Lingaratnam S; Krishnasamy M; H Martin J; Tie J; Alexander M; Michael M
J Oncol Pharm Pract; 2024 Jan; 30(1):30-37. PubMed ID: 37021580
[TBL] [Abstract][Full Text] [Related]
23. A review of real-world evidence on preemptive pharmacogenomic testing for preventing adverse drug reactions: a reality for future health care.
Chenchula S; Atal S; Uppugunduri CRS
Pharmacogenomics J; 2024 Mar; 24(2):9. PubMed ID: 38490995
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic and Pharmacogenetic Markers of Irinotecan Toxicity.
Hahn RZ; Antunes MV; Verza SG; Perassolo MS; Suyenaga ES; Schwartsmann G; Linden R
Curr Med Chem; 2019; 26(12):2085-2107. PubMed ID: 29932028
[TBL] [Abstract][Full Text] [Related]
25. The role of pharmacogenomics in adverse drug reactions.
Cacabelos R; Cacabelos N; Carril JC
Expert Rev Clin Pharmacol; 2019 May; 12(5):407-442. PubMed ID: 30916581
[TBL] [Abstract][Full Text] [Related]
26. Impact of pretreatment dihydropyrimidine dehydrogenase genotype-guided fluoropyrimidine dosing on chemotherapy associated adverse events.
Wigle TJ; Povitz BL; Medwid S; Teft WA; Legan RM; Lenehan J; Nevison S; Panuganty V; Keller D; Mailloux J; Siebring V; Sarma S; Choi YH; Welch S; Winquist E; Schwarz UI; Kim RB
Clin Transl Sci; 2021 Jul; 14(4):1338-1348. PubMed ID: 33620159
[TBL] [Abstract][Full Text] [Related]
27. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines.
Lunenburg CATC; van der Wouden CH; Nijenhuis M; Crommentuijn-van Rhenen MH; de Boer-Veger NJ; Buunk AM; Houwink EJF; Mulder H; Rongen GA; van Schaik RHN; van der Weide J; Wilffert B; Deneer VHM; Swen JJ; Guchelaar HJ
Eur J Hum Genet; 2020 Apr; 28(4):508-517. PubMed ID: 31745289
[TBL] [Abstract][Full Text] [Related]
28. Implementation of a pharmacogenomic program in a Brazilian public institution.
Suarez-Kurtz G; Kovaleski G; Elias AB; Motta V; Wolch K; Emerenciano M; Mansur MB; Palladino AM; Accioly MT; Ferreira M; Gonçalves AA; de Melo AC
Pharmacogenomics; 2020 Jun; 21(8):549-557. PubMed ID: 32378980
[TBL] [Abstract][Full Text] [Related]
29. Germline pharmacogenomics in oncology: decoding the patient for targeting therapy.
O'Donnell PH; Ratain MJ
Mol Oncol; 2012 Apr; 6(2):251-9. PubMed ID: 22321460
[TBL] [Abstract][Full Text] [Related]
30. Elucidating the role of pharmacogenetics in irinotecan efficacy and adverse events in metastatic colorectal cancer patients.
Riera P; Páez D
Expert Opin Drug Metab Toxicol; 2021 Oct; 17(10):1157-1163. PubMed ID: 34486919
[TBL] [Abstract][Full Text] [Related]
31. Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing.
Shah RR
Drug Saf; 2004; 27(3):145-72. PubMed ID: 14756578
[TBL] [Abstract][Full Text] [Related]
32. Pharmacogenomic considerations for medications in the perioperative setting.
Jhun EH; Apfelbaum JL; Dickerson DM; Shahul S; Knoebel R; Danahey K; Ratain MJ; O'Donnell PH
Pharmacogenomics; 2019 Jul; 20(11):813-827. PubMed ID: 31411557
[TBL] [Abstract][Full Text] [Related]
33. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
[TBL] [Abstract][Full Text] [Related]
34. Clinical Pharmacogenetics for Precision Medicine: Successes and Setbacks.
Chambliss AB; Marzinke MA
J Appl Lab Med; 2018 Nov; 3(3):474-486. PubMed ID: 33636912
[TBL] [Abstract][Full Text] [Related]
35. Clinical association between pharmacogenomics and adverse drug reactions.
Zhou ZW; Chen XW; Sneed KB; Yang YX; Zhang X; He ZX; Chow K; Yang T; Duan W; Zhou SF
Drugs; 2015 Apr; 75(6):589-631. PubMed ID: 25895462
[TBL] [Abstract][Full Text] [Related]
36. Population impact of pharmacogenetic tests in admixed populations across the Americas.
Suarez-Kurtz G
Pharmacogenomics J; 2021 Apr; 21(2):216-221. PubMed ID: 33110249
[TBL] [Abstract][Full Text] [Related]
37. Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation.
Cecchin E; De Mattia E; Ecca F; Toffoli G
Drug Resist Updat; 2018 Jul; 39():18-40. PubMed ID: 30075835
[TBL] [Abstract][Full Text] [Related]
38. Pharmacogenetics-based personalized therapy: Levels of evidence and recommendations from the French Network of Pharmacogenetics (RNPGx).
Picard N; Boyer JC; Etienne-Grimaldi MC; Barin-Le Guellec C; Thomas F; Loriot MA;
Therapie; 2017 Apr; 72(2):185-192. PubMed ID: 28237406
[TBL] [Abstract][Full Text] [Related]
39. Identification of pharmacogenetic variants from large scale next generation sequencing data in the Saudi population.
Goljan E; Abouelhoda M; ElKalioby MM; Jabaan A; Alghithi N; Meyer BF; Monies D
PLoS One; 2022; 17(1):e0263137. PubMed ID: 35089958
[TBL] [Abstract][Full Text] [Related]
40. Pharmacogenetics of Adverse Drug Reactions.
Osanlou O; Pirmohamed M; Daly AK
Adv Pharmacol; 2018; 83():155-190. PubMed ID: 29801574
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
